McKesson’s (NYSE:MCK) Q2 CY2026 Sales Top Estimates
McKesson (NYSE:MCK) reported Q2 CY2026 sales of $105.4B, up 7.7% year on year, exceeding Wall Street revenue estimates by 1.2%. Non-GAAP adjusted EPS was $9.93, up from $8.26, beating consensus by 4.1%. Analysts expect revenue growth of 7.3% and full-year EPS to rise from $40.82 to $45.87.
How this was made
The 30-second read
Why it matters
Traders can reassess near-term expectations for MCK based on the reported revenue and EPS outperformance, while also weighing the lack of margin leverage and the stated growth deceleration outlook.
Market read
A reported earnings beat with stable margins and a decelerating revenue outlook creates a mixed but tradable setup for MCK around the results window.
What to watch
Revenue growth is forecast to decelerate to 7.3% over the next 12 months, and adjusted operating margin remains low and stable, which could cap multiple expansion.
Background
McKesson is a major US healthcare distributor and services provider, reporting Q2 CY2026 results with revenue and adjusted EPS beats versus consensus.
Ticker impact
McKesson reported Q2 CY2026 revenue of $105.4B, up 7.7% YoY, topping estimates by 1.2% and beating adjusted EPS by 4.1%.
Bias modestly positive for the next session, with follow-through dependent on whether investors focus on margin stability versus growth deceleration.
A same-quarter beat versus consensus is a concrete catalyst, but the text also highlights low adjusted operating margin (1.3%) and only moderate growth expectations (revenue +7.3% next 12 months), limiting upside conviction.
Market effects
Supports the view that large healthcare distributors can still grow revenues, but stable low margins suggest sector profitability remains constrained.
Primarily US-focused read-through for healthcare distribution equities.
Limited global spillover beyond US healthcare supply-chain sentiment.
Counterpoint
The beat may be less about operating improvement and more about financial engineering, since the article notes EPS outperformance without adjusted operating margin expansion.
Key entities
- public_companyMcKesson
Healthcare distributor and services company reporting Q2 CY2026 revenue and adjusted EPS results.
